These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9458323)

  • 1. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Soga K; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Tangkijvanich P; Thong-ngam D; Mahachai V; Kladchareon N; Suwangool P; Kullavanijaya P
    Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
    Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
    Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.
    Hu KQ; Tong MJ
    Hepatology; 1999 Apr; 29(4):1311-6. PubMed ID: 10094980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
    Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
    Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.
    Arrieta O; Rodriguez-Diaz JL; Rosas-Camargo V; Morales-Espinosa D; Ponce de Leon S; Kershenobich D; Leon-Rodriguez E
    Cancer; 2006 Oct; 107(8):1852-8. PubMed ID: 16967451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of outcome of compensated hepatitis C virus-related cirrhosis.
    Serfaty L; Aumaître H; Chazouillères O; Bonnand AM; Rosmorduc O; Poupon RE; Poupon R
    Hepatology; 1998 May; 27(5):1435-40. PubMed ID: 9581703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.
    Bernardinello E; Cavalletto L; Chemello L; Mezzocolli I; Donada C; Benvegnú L; Merkel C; Gatta A; Alberti A
    Hepatogastroenterology; 1999; 46(30):3216-22. PubMed ID: 10626189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.